Financial, market and economic news

Ziopharm Oncology Appoints Raffaele Baffa, M.D., Ph.D., as Chief Medical Officer

Pharmaceutical Executive with 20+ Years of Experience Across All Phases of Clinical Research Including IND Submissions, Trial Design and Regulatory Filings

Former Chief Medical Officer for Servier Pharmaceuticals; Oncology R&D Leadership Roles at Shire, Pfizer and Sanofi

BOSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) — Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (NASDAQ:ZIOP) today announced the appointment of Raffaele Baffa, M.D., Ph.D., as Chief Medical Officer.

Dr. Baffa joins the Company from Medisix, an immune engineering company developing novel cellular therapies to address T cell malignancies, where he held the role of Head of R&D and Chief Medical Officer. Previously, Dr. Baffa was Vice President and Therapeutic Area Head of Oncology, Global Clinical Development for Shire, and, subsequent to the acquisition of the oncology division by Servier, Dr. Baffa served as Chief Medical Officer of Servier Pharmaceuticals. Dr. Baffa has also held industry leadership positions as Executive Director, Early Oncology Development and Clinical Research at Pfizer and at Sanofi, where he was Head of Translational Sciences – External Science & Innovation, Global Biotherapeutics.

“We’re pleased to welcome Raffaele to the Company and to the leadership team,” said Laurence Cooper, M.D., Ph.D., Chief Executive Officer. “He brings a deep understanding of engineered T cells, cancer biology, pharmacogenomics and cancer pathology, and has led early development teams in IND filings for new clinical trials for twelve compounds in the area of oncology and led late development teams in three regulatory approval submissions. We look forward to his leadership in shaping and directing our internal and external programs and partnerships to maximize the value of our distinctive and innovative science.”

Dr. Baffa …

Full story available on

Read More

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. AcceptRead More

Privacy & Cookies Policy